Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Celldex Therapeutics Inc (CLDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: CLDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $58.54
1 Year Target Price $58.54
| 10 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -45.23% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.35B USD | Price to earnings Ratio - | 1Y Target Price 58.54 |
Price to earnings Ratio - | 1Y Target Price 58.54 | ||
Volume (30-day avg) 14 | Beta 1.14 | 52 Weeks Range 14.40 - 47.00 | Updated Date 06/29/2025 |
52 Weeks Range 14.40 - 47.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.7 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -9027.19% |
Management Effectiveness
Return on Assets (TTM) -16.88% | Return on Equity (TTM) -23.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 677276149 | Price to Sales(TTM) 178.22 |
Enterprise Value 677276149 | Price to Sales(TTM) 178.22 | ||
Enterprise Value to Revenue 89.6 | Enterprise Value to EBITDA -17.34 | Shares Outstanding 66394200 | Shares Floating 56358751 |
Shares Outstanding 66394200 | Shares Floating 56358751 | ||
Percent Insiders 0.32 | Percent Institutions 113.13 |
Analyst Ratings
Rating 4 | Target Price 58.54 | Buy 2 | Strong Buy 10 |
Buy 2 | Strong Buy 10 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Celldex Therapeutics Inc
Company Overview
History and Background
Celldex Therapeutics Inc. was founded in 1982. Initially focused on antibodies for diagnostics, it evolved to concentrate on developing immunotherapies for cancer. The company has experienced pipeline setbacks and strategic shifts, including a pivot to focus on receptor tyrosine kinases.
Core Business Areas
- Antibody-Based Therapeutics: Develops monoclonal antibodies designed to modulate the immune system to fight cancer.
- Proprietary Technologies: Utilizes platforms such as its antibody-drug conjugate (ADC) technology and bispecific antibody programs.
- Clinical Development Programs: Focuses on advancing various clinical-stage drug candidates targeting specific cancers.
Leadership and Structure
Anthony Marucci is the President and CEO. The organizational structure includes research, clinical development, and commercialization teams.
Top Products and Market Share
Key Offerings
- Varlilumab: An investigational CD27 agonist antibody being evaluated in clinical trials for various cancers. While it doesn't have market share yet, it is a key pipeline asset. Competitors are checkpoint inhibitors and other immunotherapies developed by companies like Bristol Myers Squibb (BMY) and Merck (MRK).
- CDX-0159: A monoclonal antibody designed to target KIT and is in clinical development for the treatment of chronic urticaria. While it doesn't have market share yet, it is a key pipeline asset. Competitors are Xolair (Novartis (NVS)) and other drugs used to treat chronic hives.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, driven by innovation in drug discovery and development. The market is characterized by high regulatory hurdles and patent protection.
Positioning
Celldex is a biotechnology company specializing in immunotherapies. Its competitive advantage lies in its antibody-based technologies and targeted therapies.
Total Addressable Market (TAM)
The immuno-oncology market is expected to reach hundreds of billions of dollars. Celldex is positioned to capture a portion of this TAM with successful clinical trials and drug approvals.
Upturn SWOT Analysis
Strengths
- Proprietary antibody technologies
- Targeted therapy approach
- Experienced management team
- Strong research capabilities
Weaknesses
- Limited commercialized products
- Dependence on clinical trial outcomes
- High R&D expenses
- Susceptible to regulatory risks
Opportunities
- Expanding immuno-oncology market
- Partnerships and collaborations
- Successful clinical trial results
- New drug approvals
Threats
- Competition from larger pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- BMY
- MRK
- NVS
- LLY
Competitive Landscape
Celldex faces intense competition from larger pharmaceutical companies with more resources. Its competitive advantage lies in its niche focus and proprietary technologies.
Growth Trajectory and Initiatives
Historical Growth: Growth has been largely dependent on the progression of its clinical pipeline. Fluctuations are typical in this space.
Future Projections: Future growth is heavily dependent on the success of its clinical programs. Analyst estimates vary widely.
Recent Initiatives: Focus on advancing CDX-0159 and Varlilumab through clinical trials and exploring strategic partnerships.
Summary
Celldex Therapeutics is a biotechnology company with potential in its immunotherapy pipeline, particularly CDX-0159. Its success hinges on positive clinical trial outcomes. The company faces significant competition and financial risks common in the biotech industry. Strategic partnerships and successful product development are crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Financial news sources
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celldex Therapeutics Inc
Exchange NASDAQ | Headquaters Hampton, NJ, United States | ||
IPO Launch date 2008-03-10 | Founder, President, CEO & Director Mr. Anthony S. Marucci M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 186 | Website https://www.celldex.com |
Full time employees 186 | Website https://www.celldex.com | ||
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.